Unlocking the potential of remdesivir: innovative approaches to drug delivery
- PMID: 40244526
- DOI: 10.1007/s13346-025-01843-7
Unlocking the potential of remdesivir: innovative approaches to drug delivery
Abstract
Given the recurrent waves of COVID-19 and the emergence of new viral infections, optimizing the potential of remdesivir as an antiviral agent is critical. While several reviews have explored the efficacy of remdesivir, few have comprehensively addressed its challenges, such as the necessity for intravenous infusion, suboptimal lung accumulation, and safety concerns related to its formulation. This review critically examines these challenges while proposing innovative solutions and effective combinations with other antiviral agents and repurposed drugs. By highlighting the role of complex generics, we aim to enhance therapeutic efficacy in ways not previously discussed in existing literature. Furthermore, we address the development of novel drug delivery systems which specifically aim to improve remdesivir's pharmacological profile. By analyzing recent findings, we assess both the successes and limitations of current approaches, providing insights into ongoing challenges and strategies for further optimization. This review uniquely focuses on targeted drug delivery systems and innovative formulations, thereby maximizing remdesivir's therapeutic benefits and broadening its application in combating emerging viral threats. In doing so, we fill a critical gap in literature, offering a comprehensive overview that informs future research and clinical strategies.
Keywords: Advanced drug delivery systems; Complex generics; Remdesivir; Remdesivir challenges; Remdesivir combinations; Viral infections.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval: The study did not require ethics approval. Conflict of interest: The authors declare that they have no conflicts. Competing interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
An Updated Systematic Review on Remdesivir's Safety and Efficacy in Patients Afflicted With COVID-19.Cureus. 2023 Aug 7;15(8):e43060. doi: 10.7759/cureus.43060. eCollection 2023 Aug. Cureus. 2023. PMID: 37680394 Free PMC article. Review.
-
The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections.PLoS Negl Trop Dis. 2022 Mar 8;16(3):e0010220. doi: 10.1371/journal.pntd.0010220. eCollection 2022 Mar. PLoS Negl Trop Dis. 2022. PMID: 35259154 Free PMC article. Review.
-
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01814-20. doi: 10.1128/AAC.01814-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33139290 Free PMC article. Review.
-
Current Strategies of Antiviral Drug Discovery for COVID-19.Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021. Front Mol Biosci. 2021. PMID: 34055887 Free PMC article. Review.
-
Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0111721. doi: 10.1128/AAC.01117-21. Epub 2021 Jul 12. Antimicrob Agents Chemother. 2021. PMID: 34252308 Free PMC article.
References
-
- Lo MK, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Trans Med. 2019;11(494):eaau9242. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous